WO2016043524A1 - 망고스틴 추출물 또는 알파, 감마 망고스틴을 유효성분으로 포함하는 치주질환 예방 또는 개선용 조성물 - Google Patents
망고스틴 추출물 또는 알파, 감마 망고스틴을 유효성분으로 포함하는 치주질환 예방 또는 개선용 조성물 Download PDFInfo
- Publication number
- WO2016043524A1 WO2016043524A1 PCT/KR2015/009734 KR2015009734W WO2016043524A1 WO 2016043524 A1 WO2016043524 A1 WO 2016043524A1 KR 2015009734 W KR2015009734 W KR 2015009734W WO 2016043524 A1 WO2016043524 A1 WO 2016043524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mangosteen
- periodontal disease
- preventing
- composition
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Definitions
- the present invention relates to a composition for improving or preventing periodontal disease comprising a mangosteen extract or an active ingredient thereof exhibiting an excellent anti-inflammatory effect.
- Periodontal disease also known as vertigo, is an inflammatory disease accompanied by the destruction of periodontal tissue by a mixed infection of bacteria, including gingival hemorrhage, swelling, periodontal sac, loss of attachment gingiva, destruction of alveolar bone, It presents various clinical symptoms such as bad breath and is the leading cause of tooth loss and implant failure.
- This periodontal disease is a very different ' disease in terms of developing tissues, causative species and pathogenesis mechanisms in the oral cavity compared to dental caries, commonly called strata. Specifically, dental caries occurs in the teeth,
- Periodontal disease is a disease that occurs in periodontal tissue (C chalk, gingiva, periodontal ligament, alveolar bone), and dental caries is caused by bacterial species expressing organic acids (primarily lactic acid) by carbohydrate fermentation metabolism including mutans group streptococci.
- periodontal disease is mainly invented by gram negative anaerobic bacteria.
- dental caries occurs in an acidic state, while periodontal disease occurs in a basic state, because gram-negative anaerobes have more active nitrogen metabolism than glucose metabolism. As a result, a lot of tartar is generated in the place where periodontal disease occurs.
- Actinof Aggregatibacter actinomycetemcomitans; also called Actinobacillus actinomycetemcomitans.
- the mechanism of congenital immunity reaction and alveolar bone destruction caused by periodontal disease pathogens are as follows.
- Human gingival epithelial cells primarily function as a physical barrier against bacterial invasion and secrete antibacterial peptides (such as human beta defensins and LL-37).
- Antibacterial peptides such as human beta defensins and LL-37.
- gingival epithelial cells which are the primary defense membranes, are destroyed by oral microorganisms in the bacterial germ membrane, not only congenital immune response but also red woo immunity The reaction is also activated, and the destruction of the periodontal tissue is facilitated if the pathogen is not removed.
- continuity of gingival epithelium is prevented by neutrophils and antibodies from bacterial infection.
- the toxins of bacteria are neutralized by antibodies and opsonization of bacteria by complement activity results in macrophages.
- RTKL nuclearfacton B ligand
- Osteoprotegerin is secreted to regulate osteoclast differentiation do.
- human periodontal ligament fibroblasts respond to IL-1, increase RANKL expression, decrease OPG expression, promote osteoclast differentiation, and participate in alveolar bone destruction.
- gingival fibroblasts promote OPG expression in response to IL-1
- LPS of A. actinomycetemcomitans binds to TLR-4 of periodontal ligament cells, activates the p38 MAPK pathway, increases RANKL expression, increases osteoclast differentiation, and P. gingivalis is a periodontal ligament cell by Lys-gingipain. To increase RANKL expression.
- periodontal disease is a disease caused by a mixed infection by several bacterial species, most studies have been conducted only innate immunity studies for a single bacterial species.
- periodontal disease is used to improve oral hygiene, non-surgical treatment and surgical treatment (tartar removal, root lubrication, gingival sores, regeneration of periodontal tissues).
- Surgical treatment the most effective treatment, is due to the limitation of the disease progression rather than the hassle of going to the dentist and the prevention of the disease. Proceeds.
- systemic antibiotics and topical sustained-release drugs have been used, but cases of periodontal disease bacteria have been reported that result in too much drug delivery to unnecessary areas resulting in side effects and resistance to recently used antibiotics. There is a serious problem.
- LPS lipopolysaccharide
- GCSB-5 Treatment with GCSB-5 has shown that the activation of intracellular signaling agents (Akt and NF-kB), which are involved in the inflammation-causing process, reduces pain and edema.
- Akt and NF-kB intracellular signaling agents
- Mancinin Garcinia mangostana
- Mancinin is a dicotyledonous plant belonging to the Agaricaceae, native to Malaysia, and bears a slightly larger fruit than the flat ball-type table tennis ball.
- Mangosteen fruit is known to have excellent antioxidant power because it contains a representative antioxidant ingredient called xanthone, a kind of polyphenol, and has been used as a folk medicine in Thailand and Southeast Asia for a long time for the treatment of wounds such as inflammation and wounds. It is known to have been.
- Japanese Patent Laid-Open Nos. 6-98738 and 7-147951 disclose food preservatives, and Japanese Patent Laid-Open No. 5-17365 for 5 ⁇ -reducta.
- Japanese Unexamined-Japanese-Patent No. 4-244004 has whitening and anti-inflammatory action, polar solvent extract of mangosteen rind, and alpha-mangosteen
- Japanese Patent Application Laid-Open No. 10-72357 discloses antiallergic action according to antagonism of histamine and serotonin, but the effect of periodontal disease on mangosteen extract and the substance isolated therefrom It has not been disclosed at all. Under this background, the present inventors are keen to develop pharmaceutical and food compositions that exhibit excellent effects on the prevention, improvement and treatment of periodontal disease based on natural products.
- mangosteen extract and alpha-mangosteen and gamma-mangosteen isolated from it were confirmed that the antibacterial and anti-inflammatory effects against the causative agent of periodontal disease were very excellent and completed the present invention.
- One object of the present invention to provide a pharmaceutical composition for preventing or treating periodontal disease at the same time excellent antibacterial and anti-inflammatory effect.
- Another object of the present invention is to provide a food composition for preventing or improving periodontal disease at the same time excellent antibacterial and anti-inflammatory effect.
- the present invention provides a pharmaceutical composition for preventing or treating periodontal disease comprising a mangosteen extract.
- the present invention provides a pharmaceutical composition for preventing or treating periodontal disease, comprising at least one member selected from the group consisting of alpha-mangosteen and gamma-mangosteen.
- the present invention provides a food composition for preventing or improving periodontal disease, including a mangosteen extract.
- the present invention provides a food composition for preventing or improving periodontal disease, including at least one selected from the group consisting of alpha-mangosteen and gamma-mangosteen.
- composition of the present invention is a mangosteen extract or isolated therefrom
- alpha-mangosteen or gamma mangosteen exhibits excellent antimicrobial and anti-inflammatory effects on periodontal disease-causing bacteria, it can be widely used in medicine, food for preventing, improving or treating periodontal disease.
- Figure 1 illustrates the structure when formulated in the form of a nanocapsule composition comprising a mangosteen extract according to the present invention.
- Figure 2 is a photograph showing the MBC test results for the prebotella intermedia KCOM 1107 of the mangosteen extract contained in the composition of the present invention.
- Figure 3 is a Fusbacterium nucleum subsp. Of the mangosteen extract included in the composition of the present invention. MBC test results for Polymorphum KCOM 1232.
- Figure 4 is a photograph showing the MBC test results for the Aggregatibact actinomycetem mitosis KCOM 1306 of the mangosteen extract contained in the composition of the present invention.
- Figure 5 is a photograph showing the MBC test results for Porphyromonas jinjivalis ATCC 33277T of the mangosteen extract contained in the composition of the present invention.
- the present invention provides a pharmaceutical composition for preventing or treating periodontal disease, including a mangosteen extract.
- the present invention provides a food or food additive composition, oral composition for preventing or improving periodontal disease comprising a mangosteen extract.
- the mangosteen extract included in the composition according to the present invention is Malaysia, Thailand, Vietnam
- the raw material used in the study is prepared from Mangosteen (Garcinia Mangostana), a tropical fruit distributed in Malaysia, Thailand, Vietnam, Indonesia, etc.
- Mangosteen is known to contain about 40 kinds of xanthone components, and a single fruit contains a considerable amount of xanthone components.
- the mangosteen extract may be purchased commercially, or may be prepared by appropriate selection without limitation of extraction methods and extraction solvents commonly known in the pharmaceutical or food industry.
- the mangosteen can be extracted using at least one extraction solvent selected from the group consisting of water and lower alcohols having 1 to 6 carbon atoms. More preferably, alpha-mangosteen and gamma-mangosteen, which are active ingredients for periodontal disease in the mangosteen extracts, are fat-soluble substances, thus, for example, water and ethane, such as aqueous ethanol solution of less than 50 to 100%. Organic solvents or ethanol solvents can be used.
- the mangosteen extract used in the present invention 3 to 5 ethanol aqueous solution of less than 50 to 100% in 1 part by weight of mangosteen 8 to 10 hours while mixing parts by weight and refluxing in a temperature range of 60 to 80 ° C.
- the extracted liquid was filtered by an appropriate filtration method such as filtration under reduced pressure using a filtration filter or the like, and then the filtrate was removed from the extraction solvent under conditions of a temperature range of 40 to 60 ° C. and a vacuum degree of 0.2 to 0.5 atm.
- Mangosteen extract can be obtained.
- alpha-mangosteen and gamma-mangosteen are fat-soluble, they are water-soluble mangosteens in the form of inclusion compounds through an solubilization process that increases the solubility in water for effective formulation and absorption in the body.
- It may be prepared in the form of molecular encapsulation.
- further effective substances described below as necessary for the preparation of the mangosteen extract for the preparation of water-soluble mangosteen molecular capsule for enhancing the water solubility, stability and absorption of the body of the fat-soluble mangosteen extract as described above eg
- an inclusion compound such as cyclotextrin, preferably gamma-cyclodextrin.
- the mangosteen extract By mixing 0.2 to 0.5 parts by weight of gamma-cyclodextrin, the mangosteen extract can be enclosed in a range of 0.3 atm to 0.5 atm in a temperature range of 60 to 80 ° C. If necessary, in order to further stabilize the contained mangosteen extract, an additional part of arginine ⁇ is added, and stored for 4 to 8 hours at 4 degrees or less.
- It may be stabilized and may be granulated through freeze drying or the like.
- the water-soluble mangosteen molecular capsule so received may be represented in the form of a molecular capsule having a structure shown in Figure 1, it may have a particle size of about 50 to 150nm.
- the mangosteen extract is selected from the group consisting of alpha-mangosteen and gamma-mangosteen, which are xanthone components having the structures of the following formulas (1) and (2), respectively, as effective ingredients for the prevention, improvement and treatment of periodontal disease: It may include one or more components. More preferably, the composition according to the invention is said
- Alpha-mangosteen and gamma-mangosteen may be included together, preferably
- Alpha-mangosteen is 1: 1 to 5: 1, more preferably 2: 1 to 4: 1, most Preferably it may be included in a content ratio of 8.75: 2.54.
- the composition according to the present invention exhibits an excellent level of periodontal disease prevention, improvement and treatment effect.
- the composition according to the present invention may include 30 to 50% by weight of the mangosteen extract based on the weight of the total composition.
- the composition according to the present invention comprises at least one periodontal selected from the group consisting of propolis, lysozyme chloride, soybean gum, vitamin C, xylyl and vitamin E to impart synergistic effects on periodontal disease It may further comprise an active ingredient for the disease.
- the "propolis” is a material made by mixing bees and enzymes with a substance such as a resin extracted from various plants for the survival and reproduction of bees, flavones (for example, chrysin, Flavonoids such as tolysine, galangin) or flavanones (e.g., quercetin : pinostrobin), aromatic acids such as benzoic acid, coumarin benzyl esters, and various kinds such as cinnamic acid, pinobanksin, pinosembrine, etc.
- Its ingredients include antibacterial, antifungal, gastritis and gastric ulcers, analgesic effects, blood pressure and blood sugar maintenance, cardiovascular protection, and tooth protection.
- the substance such as a resin extracted from various plants for the survival and reproduction of bees, flavones (for example, chrysin, Flavonoids such as tolysine, galangin) or flavanones (e.g., quercetin : pinostrobin), aromatic acids
- Propolis can be contained in 15 to 25 parts by weight 0/0, based on the weight of the total of the composition according to the invention.
- the "soybean uncompensated substance” refers to a pure compound which is hydrophobic as a component present in soybean oil and does not react with a strong base component such as potassium hydroxide to form a soluble soap, and includes phytosterol.
- the soybean non-compensation includes components such as beta-sitosterol, campestester, stigmastea, brassicaste, resveratrol, lignan, genistein isoflavone, lecithin, phosphatidylcholine, sphingolipids, and phosphatidyl serine.
- the soybean ungummified may be included in 7 to 13% by weight relative to the total weight of the composition according to the present invention.
- These soybean gums are soft and white powder, have a peculiar smell, do not dissolve in water or alcohol, and have a big booby, so that they are not filled well when they are included in the general capsule, and are melted by frictional heat during layering. It is difficult to formulate raw materials are not well bonded.
- the soybean gums included in the present invention may be included in the composition granulated separately from the components of the other compositions.
- the "lysozyme chloride” is an enzyme that cleaves bacterial cell walls and is mainly extracted from egg whites, and transforms insoluble polysaccharides of bacterial and viral cell walls that cause gum disease into soluble polysaccharides for antibacterial activity and anti-inflammatory activity at the inflammatory site. It suppresses redness, swelling, and pain, and decomposes and discharges pus, promotes tissue repair of inflammatory sites, and heals inflammation, and also prevents gum bleeding with anti-haeparin action.
- the lysozyme chloride may be included in 10 to 20% by weight relative to the total weight of the composition according to the present invention.
- the “vitamin C '” is an antioxidant that removes free radicals in the body to prevent cell damage, promotes the synthesis of collagen, quickly regenerates the tissues of the wound, strengthens blood vessel walls, and revitalizes the action of thrombin.
- the vitamin c may be included in an amount of 3 to 10% by weight based on the total weight of the composition according to the present invention.
- the “vitamin E” is to prevent tissue damage through antioxidant action, microcirculation improving action through cell membrane stabilization, may be included in 0.5 to 2 weight 0 / ° relative to the total weight of the composition according to the present invention.
- the "Xili” is a sugar alcohol-based natural sweetener extracted from birch or oak tree, a substance capable of preventing the growth of caries bacteria due to the pentose structure, 1 to 7% by weight relative to the total weight of the composition according to the present invention Can be included
- composition according to the present invention may further comprise at least one component selected from the group consisting of seaweed powder, dry yeast and cream yeast in addition to the above additional components.
- the composition according to the present invention is the alpha- instead of the mangosteen extract itself.
- One or more selected from the group consisting of gamma-mangosteen may be included as a pharmacological component. As such, even when alpha-mangosteen and / or gamma-mangosteen are included, additional components may be included in the same manner as in the case of the mangosteen extractol pharmacological component.
- composition of the present invention further comprises one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration.
- 'pharmaceutically acceptable carrier means a known pharmaceutical excipient which is useful when formulating a pharmaceutically active compound for administration and which is substantially nontoxic and insensitive under the conditions of use. The exact ratio of these excipients depends on the solubility and chemical nature of the active compound, the chosen dosage
- compositions suitable and formulated in a form suitable excipients physiologically acceptable, disintegrating agents, sweetening agents, binding agents, coating agents, swelling agent, lubricant, 'the desired method of administration with adjuvants such as lubricants, flavoring agents of the present invention Can be.
- the pharmaceutical composition may be formulated in the form of, but not limited to, tablets, accelerators, pills, granules, powders, injections or solutions.
- Formulations of the pharmaceutical compositions and pharmaceutically acceptable carriers can be appropriately selected according to techniques known in the art, for example, see: Urquhart et al., Lancet, 16: 367, 1980 ]; Lieberman et al., PHARMACEUTICAL DOSAGE FORMS-DISPERSE SYSTEMS, 2nd ed., Vol.
- composition of the present invention may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the weight, age, sex, health status of the individual.
- the range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease.
- the daily dose of the mangosteen extract is about 60 to 90 mg
- the daily dose of alpha -mangosteen is about 5 to 9.0 mg based on the adult
- the gamma-mangosteen is 0.9 to 1.2 mg, once to several times a day It is preferable to administer in divided doses.
- the food composition When the composition according to the present invention is used for food, the food composition may be used in its own form as a dietary supplement, or may be included in other dietary supplements as an additive to the dietary supplement.
- Health functional food refers to foods that have bioregulatory functions such as prevention or improvement of disease, biological defense, immunity, recovery from illness, and inhibition of aging, and should be harmless to the human body when taken in the long term.
- the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
- Examples of the food to which the substance may be added include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, dairy products including 3 ⁇ 4, ice cream, various soups, drinks, tea, and drinks. , Alcoholic beverages and vitamin complexes, and include all dietary supplements in the usual sense.
- the food composition of the present invention comprises conventional ingredients used in the manufacture of food or food additives, specifically, flavoring agents;
- Natural carbohydrates include glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and natural sweeteners such as dextrin and cyclotextrin, or synthetic sweeteners such as saccharin and aspartame; Nutrients; vitamin; Electrolyte; coloring agent; Organic acid; Protective colloidal thickeners; pH regulators;
- Stabilizer antiseptic; glycerin; Alcohol; And carbonating agents used in the carbonated beverage.
- composition according to the invention can also be used as a composition for oral hygiene.
- it may have a formulation such as toothpaste, mouthwash, mouthwash, oral massage cream.
- the compounding composition of the composition for oral cavity provided in the present invention can be used in various combinations according to the use and type of the composition in addition to the components described above.
- Mangosteen husk (Pericarp) lkg was dried in a 25 ° C ventilated dry oven to make 250 g of dry matter with a water content of 10% or less, and then pulverized using a crusher to obtain 230 g of mangosteen husk crushed powder having a particle size of 400 mesh to 500 mesh. It was.
- the content of the active ingredient was analyzed by HPLC under the following conditions.
- Heating Oven (35 ° C) analysis showed that from the crushed mangosteen skin 400 mesh to 500 mesh
- the alpha-mangosteen content is 3.0 ⁇ 1.0% and the gamma-mangosteen content is 2 ⁇ 0.05%. Confirmed.
- a water-soluble mangosteen molecular capsule was prepared in which the mangosteen extract was solubilized according to the blending ratio shown in Table 2 below. Specifically, 45 g of gamma-cyclodextrin was mixed with 150 g of a fat-soluble mangosteen extract obtained by the method of ⁇ Production Example 2>, and the mangosteen extract was stirred at a stirring speed of 100 rpm under a temperature of 70 ° C. and 0.4 atm for 2 hours. Was enclosed. To further stabilize the inclusion mangosteen extract, 22 g of arginine is added and stored for 6 hours at 4 ° C. or lower to stabilize the capsule. This solution was then powdered via freeze drying (-40 ° C. to 40 ° C. elevated temperature, elevated temperature: rC / hr).
- composition thus prepared can be applied to all food formulations such as tablets, soft and hard capsules, liquid powder liquid vials and granule sticks.
- Example 1 Determination of Antimicrobial Activity of Streptococcus mutans ATCC 25175 of Mangosteen Extract
- a test method for determining the usefulness of the antimicrobial agent is a minimum inhibitory concentration (MIC) test and a time-kill assay test.
- MIC minimum inhibitory concentration
- MIC TEST is a test method for determining the minimum inhibitory concentration at which bacteria do not grow well, that is, the minimum amount of antimicrobial agent used to obtain a desired antimicrobial effect, and the Time-Kill assay test can maintain a desired effect for a certain time range.
- each test was conducted to test the extent to which the mangosteen extract is effective against S. aureus against Streptocccus Mutans ATCC 15175.
- the MIC test for Streptococcus mutans ATCC 25175 is the National Committee for Clinical Laboratory (NCCLS), the US standard for clinical trials.
- mangosteen extract prepared according to Preparation Example 2 and at least 99% of ethane were dissolved in a shell crush of mangosteen prepared in Preparation Example 1, followed by alpha and gamma Mangosteen was used.
- the mangosteen extract and the alpha- and gamma-mangosteens isolated therefrom exhibit antibacterial activity against Streptococcus mutans, a pathogen-associated pathogen, even at very low concentrations.
- alpha-mangosteen exhibits antimicrobial activity at only 1.0 ug / ml, which is considered to be the most effective in preventing, improving and treating periodontal disease.
- the concentration of DMSO (dimethyl sulfoxide) used as analyte sample solution was to be the final 1% by weight, and the remaining 40 weight 0 /.
- 10mg of the mangosteen extract prepared in Preparation Example 1 Prepare at 10,000 ug / ml.
- the concentration of the sample to be analyzed solubilizers DMSO (dimethyl sulfoxide), and used as to a final weight of 10 0/0, the remaining 40 parts by weight 0 / were used for the test was prepared by adding a BHI medium.
- test solution was prepared by diluting the 10,000 ug / ml mangosteen extract thus prepared to a final concentration of 10, 100 and 1000 ug / ml, respectively, according to the composition ratio as shown in Table 7 below.
- the strain used, Streptococcus mutans ATCC 25175, is 50% by weight.
- test solution 100 prepared at the concentration-specific ratio as shown in Table 7 above was cultured under the same conditions as in the MIC experiment.
- the number of bacteria that formed colonies after 48 hours of incubation at 37 ° C. in solid BHI medium was counted, and the results are shown in Table 8 below.
- the solid medium dilution method was carried out. Specifically, the test bacteria were tested for the active strains up to the logarithmic period in a medium in which 5% of sheep blood, hemin 5 / ig / ml and 0.5 g / ml of menadione were added to Trypticase soy agar (TSA).
- TSA Trypticase soy agar
- the medium was mixed with multiple dilutions of Brucella agar in a medium containing 5% hemolytic sheep blood, hemin 5 / g / ml and vitamin K1 g / ml, and the final concentration in the medium was 0.25 / zg / ml to 128 //. Prepared to be g / ml.
- the mangosteen extract according to the present invention is porphyromonas
- Genjivalis (Porphyromonas gingivalis CCARM 0145) was found to exhibit a MIC of about 120 ig / ml.
- Example 3 Antimicrobial Determination of Mangosteen Extracts against Various Periodontal Diseases
- Prevotella intermedia KCOM 1107 a causative agent of periodontal disease isolated from oral cavity of Koreans, was identified. Fusbacterium nucleatum subsp. polymorphum KCOM 1232, Aggregatibacter
- the minimum bactericidal concentration (MBC) was measured by
- the antimicrobial activity of mangosteen 3 ⁇ 4 quality extract was measured.
- the strains 0.5% yeast extract, 0.05% cysteine HC1-H20, 0.5 in Tryptic Soy broth Inoculated in medium containing mg / ml hemin and 2 ug / ml vitamin Kl, 37 ° C anaerobic chamber (Bactron I, Sheldon Manufacturing Inc., Cornelius, OR, USA) and anaerobic conditions (10% H 2 5% C0 2 , 85% N 2 ).
- MBC measurement was used by modifying the micro-dilution method presented by the Clinical and Laboratory Standards Institute (CLSI) [1]. Bacteria were inoculated in the above-mentioned medium, incubated in a bacterial incubator at 37 ° C for 24 hours, diluted to l xl 6 CFU / ml, and dispensed into 96-well plates.
- CLSI Clinical and Laboratory Standards Institute
- the mangosteen extract prepared in Preparation Example 2 was prepared in Table 7.
- composition (MBL-Wmg 02), it was added to the bacterial culture solution to be diluted 8 stages twice from 2000 ug / ml.
- the negative control was to use only the bacterial culture solution
- the positive control was used commercially available gargle (listerin ®, Johnson & Johnson). After dispensing 200 ul into 96 well plates, they were incubated for 48 hours at 37 ° C. After taking lOul from the bacterial culture solution, they were plated in agar medium and incubated for 48 hours at 37 ° C. The minimum concentration was determined so that% bacteria did not grow. Each reaction was repeated three times. The results are shown in Table 9 and FIGS. 2 to 5.
- the water-soluble mangosteen extract molecular capsule (MBL-Wmg 02) is a prevotella intermedia belonging to the main causative species of periodontal disease than mangosteen extract (MBL-Wmg 01).
- actinomycetemcomitans is a major pathogenic species for certain periodontal diseases such as prepubertal periodontitis, and in adult periodontitis belonging to most periodontal diseases.
- the mangosteen bark extracts MBL-Wmg 01 and MBL-Wmg 02 according to the present invention are 2.0 mg / ml and 250 g / It can be used very effectively in food additives, oral hygiene products (toothpaste, gargle, etc.) and dietary supplements for the prevention of periodontal disease above ml.
- oral hygiene products teethpaste, gargle, etc.
- dietary supplements for the prevention of periodontal disease above ml.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580055398.1A CN106794210A (zh) | 2014-09-16 | 2015-09-16 | 包含山竹提取物或α、γ倒捻子素作为有效成分的牙周病预防或改善用组合物 |
JP2017535590A JP6387467B2 (ja) | 2014-09-16 | 2015-09-16 | マンゴスチン抽出物またはアルファ、ガンママンゴスチンを有効成分として含む歯周疾患の予防または改善用組成物 |
US15/510,384 US10022412B2 (en) | 2014-09-16 | 2015-09-16 | Composition for preventing or alleviating periodontal diseases, containing, as active ingredient, mangosteen extract or α- or γ-mangosteen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0122945 | 2014-09-16 | ||
KR1020140122945A KR101775613B1 (ko) | 2014-09-16 | 2014-09-16 | 망고스틴 추출물 또는 알파, 감마 망고스틴을 유효성분으로 포함하는 치주질환 예방 또는 개선용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016043524A1 true WO2016043524A1 (ko) | 2016-03-24 |
Family
ID=55533495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/009734 WO2016043524A1 (ko) | 2014-09-16 | 2015-09-16 | 망고스틴 추출물 또는 알파, 감마 망고스틴을 유효성분으로 포함하는 치주질환 예방 또는 개선용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10022412B2 (ko) |
JP (1) | JP6387467B2 (ko) |
KR (1) | KR101775613B1 (ko) |
CN (1) | CN106794210A (ko) |
WO (1) | WO2016043524A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112501070A (zh) * | 2020-12-14 | 2021-03-16 | 河南科技大学第一附属医院 | 原代分离牙龈卟啉单胞菌的培养基及其制备方法和应用 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101978377B1 (ko) * | 2017-06-27 | 2019-05-15 | 동의대학교 산학협력단 | 치아 미백용 스티커 |
KR20190046438A (ko) | 2017-10-26 | 2019-05-07 | (주)예스킨 | 만성 치주질환 개선 식품조성물 |
KR101879398B1 (ko) * | 2017-12-20 | 2018-07-18 | 주식회사 메디바이오랩 | 망고스틴 추출물 및 프로폴리스 추출물을 포함하는 골형성 촉진용 조성물 및 이의 제조방법 |
KR101989971B1 (ko) * | 2018-09-13 | 2019-06-17 | 주식회사 메디바이오랩 | 망고스틴 추출물을 포함하는 근관 세척용 조성물 |
TWI732309B (zh) * | 2018-10-10 | 2021-07-01 | 蘇娥 梁 | 補虛損保健品組合物及其製備方法和其應用 |
CN109463386B (zh) * | 2018-10-25 | 2020-09-01 | 华南农业大学 | 倒捻子素在防治青枯病中的应用 |
JP6871555B2 (ja) * | 2019-10-04 | 2021-05-12 | 国立大学法人大阪大学 | 歯周病菌細胞侵入抑制用組成物 |
US10898533B1 (en) | 2020-01-26 | 2021-01-26 | King Saud University | Mangosteen nanoparticles |
CN111357909A (zh) * | 2020-04-02 | 2020-07-03 | 吉林农业科技学院 | 山竹多糖降血糖固体饮料纯化工艺及测定实验方法 |
KR102585928B1 (ko) * | 2020-11-13 | 2023-10-06 | 주식회사 메디바이오랩 | 망고스틴 추출물을 포함하는 근관 충전용 조성물 |
CH718673B1 (fr) * | 2021-05-28 | 2024-06-14 | Vixelia | Compositions de soins bucco-dentaires. |
KR102473231B1 (ko) * | 2022-05-19 | 2022-12-01 | 한국교통대학교산학협력단 | 망고스틴 과피 추출물 또는 이의 주요성분을 포함하는 클로스트리디움 디피실 항균 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11343247A (ja) * | 1998-05-29 | 1999-12-14 | Sumitomo Forestry Co Ltd | グルコシルトランスフェラーゼ阻害剤 |
JP2003231607A (ja) * | 2002-02-05 | 2003-08-19 | Hosoda Shc:Kk | マンゴスチン抽出物及びその含有抗菌消臭剤 |
JP2004194554A (ja) * | 2002-12-17 | 2004-07-15 | Gifu International Institute Of Biotechnology | 健康食品 |
JP2008127304A (ja) * | 2006-11-18 | 2008-06-05 | Tokyo Dental College | 歯質強化剤及びこれを含有する口腔用組成物並びに飲食物とそれらの製造方法 |
KR20110060154A (ko) * | 2009-11-30 | 2011-06-08 | (주)아모레퍼시픽 | 한방 발효 추출물을 함유하는 구강용 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07147951A (ja) | 1991-01-25 | 1995-06-13 | Asama Kasei Kk | 食品用保存剤および保存性の優れた食品の製造法 |
JP2890212B2 (ja) | 1991-01-29 | 1999-05-10 | 有限会社野々川商事 | 化粧料 |
JP3010566B2 (ja) | 1991-07-03 | 2000-02-21 | 有限会社野々川商事 | テストステロン 5α−レダクターゼ阻害剤 |
JPH0698738A (ja) | 1992-01-20 | 1994-04-12 | Asama Kasei Kk | 食品用保存剤 |
JPH07250658A (ja) | 1994-03-11 | 1995-10-03 | Dainippon Ink & Chem Inc | 抗菌剤 |
JPH08208501A (ja) | 1995-02-08 | 1996-08-13 | Terumo Corp | ガルシニア マンゴスタナl.の抽出物を含有する抗ヘリコバクター・ピロリ薬 |
JPH0987155A (ja) | 1995-09-27 | 1997-03-31 | Shiseido Co Ltd | 紫外線吸収剤及びそれを配合した皮膚外用剤 |
JP3968405B2 (ja) | 1996-08-30 | 2007-08-29 | 株式会社ロッテホールディングス | 抗アレルギー剤 |
JP4035185B2 (ja) | 1996-10-18 | 2008-01-16 | 日本メナード化粧品株式会社 | セリンプロテアーゼ阻害剤 |
JP4150104B2 (ja) | 1998-05-13 | 2008-09-17 | 新日本石油株式会社 | 防食塗料組成物 |
JP4630416B2 (ja) * | 2000-03-02 | 2011-02-09 | 株式会社ロッテ | 坑う蝕、歯周病剤 |
JP4638977B2 (ja) | 2000-08-02 | 2011-02-23 | 株式会社ロッテ | シクロオキシゲナーゼ阻害剤 |
JP2003171301A (ja) * | 2001-11-09 | 2003-06-20 | Mahidol Univ | 歯周炎治療における補助剤としてのカルメグゲル |
US20050266018A1 (en) * | 2004-05-27 | 2005-12-01 | Boreyko Benson K | Nutraceutical compositions with mangosteen |
FR2918845B1 (fr) * | 2007-07-19 | 2012-11-30 | Roquette Freres | Agent d'encapsulation comprenant une maltodextrine de pois et/ou un sirop de glucose de pois,compositions le contenant et son procede de preparation |
CN101428044A (zh) * | 2007-11-06 | 2009-05-13 | 王莉 | 一种治疗多种口腔疾病的新型广普抗炎镇痛药物 |
WO2009112054A1 (en) * | 2008-03-10 | 2009-09-17 | Phf S.A. | High bioavailability formulation of mangosteen and manufacturing process thereof |
WO2011068814A1 (en) * | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
-
2014
- 2014-09-16 KR KR1020140122945A patent/KR101775613B1/ko active IP Right Grant
-
2015
- 2015-09-16 CN CN201580055398.1A patent/CN106794210A/zh active Pending
- 2015-09-16 WO PCT/KR2015/009734 patent/WO2016043524A1/ko active Application Filing
- 2015-09-16 JP JP2017535590A patent/JP6387467B2/ja active Active
- 2015-09-16 US US15/510,384 patent/US10022412B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11343247A (ja) * | 1998-05-29 | 1999-12-14 | Sumitomo Forestry Co Ltd | グルコシルトランスフェラーゼ阻害剤 |
JP2003231607A (ja) * | 2002-02-05 | 2003-08-19 | Hosoda Shc:Kk | マンゴスチン抽出物及びその含有抗菌消臭剤 |
JP2004194554A (ja) * | 2002-12-17 | 2004-07-15 | Gifu International Institute Of Biotechnology | 健康食品 |
JP2008127304A (ja) * | 2006-11-18 | 2008-06-05 | Tokyo Dental College | 歯質強化剤及びこれを含有する口腔用組成物並びに飲食物とそれらの製造方法 |
KR20110060154A (ko) * | 2009-11-30 | 2011-06-08 | (주)아모레퍼시픽 | 한방 발효 추출물을 함유하는 구강용 조성물 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112501070A (zh) * | 2020-12-14 | 2021-03-16 | 河南科技大学第一附属医院 | 原代分离牙龈卟啉单胞菌的培养基及其制备方法和应用 |
CN112501070B (zh) * | 2020-12-14 | 2021-11-23 | 河南科技大学第一附属医院 | 原代分离牙龈卟啉单胞菌的培养基及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20160032801A (ko) | 2016-03-25 |
CN106794210A (zh) | 2017-05-31 |
JP6387467B2 (ja) | 2018-09-05 |
JP2017529400A (ja) | 2017-10-05 |
US20170296604A1 (en) | 2017-10-19 |
US10022412B2 (en) | 2018-07-17 |
KR101775613B1 (ko) | 2017-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10022412B2 (en) | Composition for preventing or alleviating periodontal diseases, containing, as active ingredient, mangosteen extract or α- or γ-mangosteen | |
KR100835899B1 (ko) | 생강 추출물 또는 이로부터 분리된 진저롤을 포함하는치주질환의 예방 또는 치료용 조성물 | |
KR101841181B1 (ko) | 생약 추출물을 함유하는 치약 조성물 | |
WO1999055298A1 (fr) | Compositions alimentaires, compositions orales et compositions medicinales servant a prevenir ou traiter la parodontose et procede de prevention ou de traitement de la parodontose | |
RU2504368C2 (ru) | ЖЕВАТЕЛЬНАЯ ТВЕРДАЯ КОМПОЗИЦИЯ И СПОСОБ ПОДАВЛЕНИЯ РАЗВИТИЯ Streptococcus mutans | |
KR20190000955A (ko) | 혼합 추출물을 함유하는 치주질환 예방 또는 치료용 조성물 | |
KR101225114B1 (ko) | 봉독을 유효성분으로 함유하는 피부 미백 및 피부질환 예방 및 치료용 조성물 | |
Li et al. | Phyllanthus emblica fruits: A polyphenol-rich fruit with potential benefits for oral management | |
KR20130097537A (ko) | 강황, 석창포, 원지의 열수추출물의 혼합물을 유효성분으로 포함하는 인지력 및 기억력 향상용 조성물 | |
JP2007332081A (ja) | 健康美容機能性組成物、それを含有する飲食品および化粧品 | |
JP2007051096A (ja) | 口腔用組成物 | |
KR20200135111A (ko) | 용해도 및 항염증 효과가 향상된 매스틱 검이 포집된 지질나노입자를 유효성분으로 함유하는 잇몸 질환의 예방 또는 치료용 조성물 | |
KR20140037316A (ko) | 금은화 추출물을 포함하는 크론병 치료 또는 예방용 약학조성물 | |
KR101447007B1 (ko) | 디프테로카퍼스 옵터시포리어스 추출물을 유효성분으로 함유하는 노화방지용 조성물 | |
KR100530578B1 (ko) | 항균활성을 갖는 키토산, 키토산올리고당 및 자몽종자추출물을 함유한 약학조성물 | |
KR101280868B1 (ko) | 야콘 추출물을 유효성분으로 함유하는 충치와 치주질환 예방 또는 치료용 약학조성물 및 식품 조성물 | |
JP4413272B1 (ja) | ヒアルロン酸産生促進剤 | |
JP2015071623A (ja) | オレウロペインおよびその分解物を含有する歯周組織健康維持剤 | |
KR101561441B1 (ko) | 도깨비가지 추출물을 유효성분으로 함유하는 치주질환 예방 또는 치료용 조성물 | |
KR101574678B1 (ko) | 가시상추 추출물을 유효성분으로 함유하는 치주질환 예방 또는 치료용 조성물 | |
KR20240118273A (ko) | 곰보배추 및 해동피의 혼합추출물을 유효성분으로 포함하는 치주질환의 예방, 개선 또는 치료용 조성물 | |
RU2484842C2 (ru) | Средство, обладающее общеукрепляющим, адаптогенным и препятствующим снижению иммунитета действием, и способ его получения | |
KR20220121946A (ko) | 오배자 추출물 및 자일리톨을 포함하는 구강 건강을 위한 조성물 | |
RU2482862C2 (ru) | Лечебно-профилактический препарат "мумие очищенное. раствор водно-спиртовой" | |
CA3226434A1 (en) | Composition comprising horse chestnut extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15841905 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15510384 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017535590 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/07/2017) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15841905 Country of ref document: EP Kind code of ref document: A1 |